Equity Profile

VRTX

Vertex Pharmaceuticals Incorporated

Health CareBiotechnology$121.9B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Vertex Pharmaceuticals Incorporated is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases, particularly cystic fibrosis. With a market cap of $122 billion, it plays a significant role in the healthcare sector, addressing unmet medical needs and advancing treatment options.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and financial health, indicating how much profit is attributed to each share.

$4.50

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and maintain competitive advantage.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VRTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.42%

Avg Stock Reaction

+0.86%

Last Quarter Recap

In Q1-2026, Vertex reported an EPS of $4.47, surpassing expectations by 21.2%. The stock reacted positively, gaining 1.4% the following day.

Management Promises & Guidance

Continue to invest in research and development for new therapies.
Expand market access for existing treatments.
Focus on improving patient outcomes through innovative solutions.

Expectations

Wall Street Expectations

Overall, investors are optimistic about Vertex's upcoming earnings, especially given its strong track record of beating EPS estimates. However, there are concerns about revenue growth and market competition.

Bull Case

If Vertex continues its trend of exceeding EPS estimates, it could signal strong operational efficiency and market demand for its products, leading to a positive stock reaction.

Bear Case

On the other hand, if the company fails to meet revenue expectations or faces increased competition, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$4.50

EPS is a critical measure of the company's profitability and financial health, indicating how much profit is attributed to each share.

Revenue Growth

N/A

Revenue growth is essential to assess the company's ability to expand its market presence and maintain competitive advantage.

Cystic Fibrosis Treatment Sales

N/A

Sales from cystic fibrosis treatments are a major revenue driver for Vertex, and any changes could significantly impact overall performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Vertex's history of beating EPS estimates, this figure will be crucial for investor confidence and stock performance.

How are cystic fibrosis treatment sales trending?

Sales trends in this key segment will significantly impact overall revenue and future growth prospects for the company.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Vertex's ability to maintain strong EPS growth due to its innovative pipeline and market leadership in cystic fibrosis treatments.

Supporting Evidence

Vertex has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened investor interest.

Recent trends in cystic fibrosis treatment demand may not be fully reflected in analyst forecasts.

Key Risk

If cystic fibrosis treatment sales exceed expectations, it could significantly alter the growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Vertex's ability to maintain its growth trajectory amid increasing competition and market dynamics.

Bull Confirmed If

An EPS of $4.50 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $4.00 would confirm the bear case, raising concerns about profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±13.77%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant potential movement in Vertex's stock, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±13.8% while VRTX has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.6%

Calls (43K)P/C Ratio: 1.96Puts (79K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vertex beats expectations, history suggests the stock could rise by about 0.69%, confirming strong operational performance.

In-Line / Cautious

If results come in as expected, the stock may experience muted movement as investors digest management's commentary.

Miss

Should the company miss expectations, history suggests an average drop of about 2.03%, indicating potential investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline for new therapies.
2Details on market access strategies for existing products.
3Insights into competitive pressures in the cystic fibrosis market.
4Management's outlook on revenue growth for the upcoming quarters.
5Any commentary on patient outcomes and satisfaction with current therapies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a critical measure of the company's profitability and financial health, indicating how much profit is attributed to each share.

$4.50

Revenue Growth

Revenue growth is essential to assess the company's ability to expand its market presence and maintain competitive advantage.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VRTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+15.42%

Avg Stock Reaction

+0.86%

Last Quarter Recap

In Q1-2026, Vertex reported an EPS of $4.47, surpassing expectations by 21.2%. The stock reacted positively, gaining 1.4% the following day.

Management Promises & Guidance

Continue to invest in research and development for new therapies.
Expand market access for existing treatments.
Focus on improving patient outcomes through innovative solutions.

Expectations

Wall Street Expectations

Bull Case

If Vertex continues its trend of exceeding EPS estimates, it could signal strong operational efficiency and market demand for its products, leading to a positive stock reaction.

Bear Case

On the other hand, if the company fails to meet revenue expectations or faces increased competition, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$4.50

EPS is a critical measure of the company's profitability and financial health, indicating how much profit is attributed to each share.

Revenue Growth

N/A

Revenue growth is essential to assess the company's ability to expand its market presence and maintain competitive advantage.

Cystic Fibrosis Treatment Sales

N/A

Sales from cystic fibrosis treatments are a major revenue driver for Vertex, and any changes could significantly impact overall performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given Vertex's history of beating EPS estimates, this figure will be crucial for investor confidence and stock performance.

How are cystic fibrosis treatment sales trending?

Sales trends in this key segment will significantly impact overall revenue and future growth prospects for the company.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Vertex's ability to maintain strong EPS growth due to its innovative pipeline and market leadership in cystic fibrosis treatments.

Supporting Evidence

Vertex has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened investor interest.

Recent trends in cystic fibrosis treatment demand may not be fully reflected in analyst forecasts.

Key Risk

If cystic fibrosis treatment sales exceed expectations, it could significantly alter the growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Vertex's ability to maintain its growth trajectory amid increasing competition and market dynamics.

Bull Confirmed If

An EPS of $4.50 or higher would confirm the bull case and indicate strong operational performance.

Bear Confirmed If

An EPS below $4.00 would confirm the bear case, raising concerns about profitability and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±13.77%

Historical Avg

±0.9%

Pricing rich

The options market is pricing in a significant potential movement in Vertex's stock, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±13.8% while VRTX has averaged ±0.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

19.6%

Calls (43K)P/C Ratio: 1.96Puts (79K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Vertex beats expectations, history suggests the stock could rise by about 0.69%, confirming strong operational performance.

In-Line / Cautious

If results come in as expected, the stock may experience muted movement as investors digest management's commentary.

Miss

Should the company miss expectations, history suggests an average drop of about 2.03%, indicating potential investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·1 sell

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

R-OHDavid J. TaylorRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline for new therapies.
2Details on market access strategies for existing products.
3Insights into competitive pressures in the cystic fibrosis market.
4Management's outlook on revenue growth for the upcoming quarters.
5Any commentary on patient outcomes and satisfaction with current therapies.